Dianthus Therapeutics, Inc. (DNTH)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $86.98
- As of
Kresmion compiles this page from DNTH's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Dianthus Therapeutics, Inc. /DE/ (DNTH): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-04.
See the full DNTH dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for DNTH on one page. Preview it with sample data, then open it live with a free account.
Preview the DNTH dossierActive events for DNTH
- mediumEarnings above estimates
Q3-2026: Beat consensus by 19.1%, EPS $-0.81 vs $-1.001 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +302% to DNTH (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +8927% to DNTH (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 65% of DNTH (2026Q2)
- high13F: large reduction
D. E. Shaw & Co., Inc. cut 71% of DNTH (2026Q2)
FREE, NO ACCOUNT
Every event on DNTH, as it fires
You are seeing 5 of 10 events recorded on DNTH since 2026-05-26.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, DNTH
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on DNTH
DNTH against its peers
DNTH's operating margin of -8739.3% ranks in the 9th percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-09-30.
| Metric | DNTH | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.0M USD | 208M USD | 9 | 16 |
| Operating margin | -8739.3% | -156.9% | 9 | 15 |
| Net margin | -7973.3% | -160.6% | 9 | 15 |
| Return on equity | -32.9% | -34.8% | 50 | 22 |
| 1 year | 119.5% | 43.1% | 70 | 21 |
Peers (25): APLS.D, GRAL, PTCT, TVTX, EWTX, ERAS, DFTX, MANE, SRRK, COGT, IONS, RLAY, MIRM, BLTE, CNTA.D, IMVT, LGND, IBRX, CRSP, ARWR, CGON, KOD, ORKA, CPRX.D, XENE. Fiscal periods ending between 2025-12-31 and 2026-09-30. Every figure is one full fiscal year read from one annual filing (DNTH: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in DNTH on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on DNTH in the last 180 days.
Upstream: SEC EDGAR filings for DNTH
Kresmion, "Dianthus Therapeutics, Inc. /DE/ (DNTH) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/DNTH. Upstream data: SEC EDGAR filings for DNTH.
Link to this data (HTML):
<a href="https://kresmion.com/research/DNTH">Dianthus Therapeutics, Inc. /DE/ (DNTH) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow DNTH on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to DNTH for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.